New drug aims to strengthen bones in kids with rare brittle bone disease

NCT ID NCT06636071

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 study tests setrusumab, a monthly IV infusion, in 6 Japanese children with osteogenesis imperfecta (types I, III, or IV), a condition that causes fragile bones and frequent fractures. The main goal is to see if the drug lowers the number of fractures, including spine fractures. All participants have had at least one fracture in the past year and have used or are using bisphosphonate therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
setrusumab (a monoclonal antibody given by IV infusion once a month)
What this could lead to
If it works, this could point toward a treatment that lowers fracture rates in children with brittle bone disease.
What could go wrong
This is a small, open-label study with only 6 participants, so results may not apply broadly. Setrusumab may not reduce fractures as hoped, and side effects from the infusion are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Keio University Hospital

    Tokyo, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Osaka University Hospital

    Osaka, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.